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ABSTRACT 
Rituximab can be used for the treatment of severe rheumatoid arthritis, 
follicular lymphoma phase III-IV, follicular non-hodgkins lymphoma, 
chronic lymphocytic leukimia therapy, advance therapy of 
granulomatosis polyangiitis and microscopic polyitis. Rituximab is a 
two compartment with an average half-life of 87 ± 18 hours and a 
volume distribution of 1.3L. Administration of rituximab at a dose of 
375 mg / m2 in 4 consecutive weeks can increase serum drug 
concentration in each administration by infusion. This review article 
focuses on biosimilar technology of rituximab was carried out by 
increasing the teraupetic mechanism and the response to the potential 
effects of binding B-mAB in NHL disease. The development of 
biosimilar rituximab approved by the FDA, namely ofatumab (anti CD20) and Obinutuzumab 
(mAb from rituximab with a different glucose group).  
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FORMULATION  
The use of Rituximab intravenously is given based on body surface area (BSA), dose 
calculation, and preparation using aseptic techniques. The disadvantage of using intravenous 
Rituximab is the use of an intravenous catheter and infusion-related reactions and patient 
discomfort. Therefore, a formulation of rituximab using subcutaneously developed with 
consideration of this administration can limit the volume of the drug to the level and number 
of drugs capable of reaching the vascular system and lymph tissue. The development of a 
drug delivery system, a highly concentrated rituximab formulation to reduce the volume of 
administration to 11.7 ml, but for its development required a reduction in the resistance that 
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occurs in sub-cutaneous administration. Human recombinant enzymes derived from DNA 
derivates (alpha voryaluronidase) were developed to overcome subcutaneous drug 
bioavailability barriers. By depolymerizing the viscoelastic component of the extracellular 
matrix (hyaluronan), alpha voryaluroidase reversibly alters the matrix structure and increases 
the rate of absorption of the drug and reduces locally injected drug resistance through 
conformation with alpha vorhyaluronidase. So that Rituximab administered subcutaneously 
at a fixed dose capable of achieving bioavailability is equivalent to the formulation of 




Rituximab is a two compartment with an average half-life of 87 ± 18 hours and a volume 
distribution of 1.3L. Cmax concentration of rituximab is very dependent on the dose of the 
drug given. This is because the administration of rituximab at a dose of 375 mg / m2 in 4 
consecutive weeks can increase serum drug concentration in each administration by infusion 
with a median value of Cmax of 239 to 460 µg / mL sequentially. Rituximab diffuses in the 
central nervous system (CNS) are not found in some organs such as the kidneys, lungs, liver, 
and lymph glands.
[3]
 Rituximab is a monoclonal antibody drug that has an effect on B-cells 
and specifically on CD20 cell targets. CD20 cells are a typical part of only pre-B cells and 
mature B lymphocytes as shown in Figure 1. Rituximab will only bind to the CD20 cell 
portion of B lymphocyte cells by triggering the lymphocyte cell apoptosis process and 




Picture 1: Schemic Illustration of Rituximab Action Mechanism.
[4]
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CLINICAL USE  
Rituximab can be used for the treatment of severe rheumatoid arthritis, follicular lymphoma 
phase III- IV, follicular non-hodgkins lymphoma, chronic lymphocytic leukemia therapy, 




SIDE EFFECTS  
Side effects that appear including fever, hypotension, bronchospasm, urticaria and 
angioedema. These side effects generally occur at 8% when administering the first infusion. 
In addition, rituximab can cause Stevens-Johnson reactions and necrolysis of cells in the 
epidermal part of the skin. Rituximab also has side effects such as infection with Lysis 
Syndrome, and hepatitis. In addition, rituximab can cause back pain, dizziness, and 
depression after drug use. Long-term use of rituximab can cause opportunistic infections such 
as pneumonia, parvovirus B19, varicella, cytomegalovirus, or the herpes simplex virus. 
Rituximab can cause hepatitis-B reactivation, which aggravates the condition of hepatitis and 
causes hepatic failure. In the use of rituximab, careful attention must be paid to the overall 
condition of the patient's body and monitoring of the condition of the patient.  
  
BIOSIMILAR OF RITUXIMAB  
Biosimilar is a copy drug or similar biological product that has biological effects and 
activities such as available drugs or products or innovator drugs. Biosimilars are intended to 
increase security and effectiveness that are comparable or better than innovator products that 
have been off-paten.
[5]
 Rituximab has several biosimilars can be seen in table 1.  
 




Drug Phase of 











Phase III LTBFL Terminated - 
PF- 
05280586 




Phase I  FL Terminated - 








Approved ASFL Launched 72 % 
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ASFL, Advanced Stage Follicular Lymphoma. CLL, Chronic Lymphocytic Leukemia. DLBCL, Diffuse 
Large B-Cell 
Lymphoma. FL, 
Follicular Lymphoma. INHL, Indcient non-Hodgkin Lymphoma. LTBFL, Low Tumor Burden Follicular 
Lymphoma. *Price varies depending on the market and the country. 
 
USE IN INDONESIA  
Rituximab is included in several recommendations in setting standards for therapy related to 
the handling of specific diseases. Table 2. Concerning the Regulation of the Decree of the 
Minister of Health of the Republic of Indonesia Number HK.02.02 / MENKES / 523/2015, 
the National Formulary states that rituximab can be given to patients with certain conditions. 
Another regulation states that this drug can be given to patients with acute, moderate and 
severe levels of lymphoma and leukemia in the INA- CBG program included in the National 
Health Insurance program (JKN).
[7,8]
 The treatment of lymphoma therapy can help in 
handling public health in Indonesia.  
 
Table 2: The use of Rituximab according to the regulations of KEPMENKES 2015. 
Therapy Dosage Form Notes 
For all types of Non-Hodgkins Lymphoma 




Maximum prescription is 
375 mg / m2 every 3 weeks. 
For Chronic Lymphocytic Leukemia (CLL) 




Maximum prescription is 
375 mg / m2 every 3 weeks. 
 
COST  
The use of rituximab, according to Chaltron et al 2010, generally requires a cost of $ 630 to 
10-mg / vial with a regimen dosage range ranging from 375 to 500 mg / m2 to 4 times of 
administration. This is of course adjusted to the desired dosage and therapy. However, the 
drug can be given up to 1000 mg for the treatment of rheumatoid arthritis. The price of 




RECENT DEVELOPMENT  
The development of rituximab was carried out by increasing the therapeutic mechanism and 
the response to the potential effects of binding B-mAb in NHL disease, hence biosimilar 
rituximab approved by the FDA was developed, namely ofatumumab and obinutuzumab. 
Ofatumumab is an anti CD20 that is able to bind epitopes differently from CD20, whereas 
obinutuzumab is mAb from rituximab with a different glucose group.
[6]
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CONCLUSION  
Rituximab was discovered in 1975 and continued to be developed in 1980. This drug is 
continuously developed to be able to create the development of biosimilar drugs, namely 
ofatumumab and obinutuzumab. The use of rituximab is permissible for Indonesian society 
because it is supported by the government in the available MAB use options, and NHL 
therapy in particular. However, the use of rituximab needs therapeutic evaluation in its use, 
therefore, it can handle side effects well.  
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